Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.

Ohata Y, Tomita Y, Sunakawa K, Drusano GL, Tanigawara Y.

Int J Antimicrob Agents. 2019 Sep;54(3):292-300. doi: 10.1016/j.ijantimicag.2019.06.021. Epub 2019 Jul 3.

PMID:
31279154
2.

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.

Kawata T, Higashimori M, Itoh Y, Tomkinson H, Johnson MG, Tang W, Nyberg F, Jiang H, Tanigawara Y.

Cancer Chemother Pharmacol. 2019 May;83(5):849-858. doi: 10.1007/s00280-019-03788-4. Epub 2019 Feb 14.

3.

Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.

Miura Y, Imamura CK, Uchino K, Kishida T, Matsubara N, Shinojima T, Kondo K, Hongo F, Yoshimura K, Tanigawara Y, Takano T.

Clin Genitourin Cancer. 2019 Feb;17(1):e1-e11. doi: 10.1016/j.clgc.2018.09.015. Epub 2018 Sep 29.

PMID:
30529389
4.

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.

Kawamura T, Kasai H, Fermanelli V, Takahashi T, Sakata Y, Matsuoka T, Ishii M, Tanigawara Y.

Cancer Sci. 2018 Sep;109(9):2822-2829. doi: 10.1111/cas.13708. Epub 2018 Jul 23.

5.

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Review.

PMID:
29923599
6.

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.

Nakamura T, Toshimoto K, Lee W, Imamura CK, Tanigawara Y, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):474-482. doi: 10.1002/psp4.12307. Epub 2018 Jun 19.

7.

Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.

Mori Y, Kasai H, Ose A, Serada M, Ishiguro M, Shiraki M, Tanigawara Y.

Osteoporos Int. 2018 May;29(5):1155-1163. doi: 10.1007/s00198-018-4376-1. Epub 2018 Feb 8.

8.

Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.

Kawamura T, Kenmotsu H, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Omae K, Mori K, Tanigawara Y, Nakajima T, Ohde Y, Endo M, Takahashi T.

Clin Lung Cancer. 2018 Mar;19(2):e247-e252. doi: 10.1016/j.cllc.2017.07.002. Epub 2017 Aug 10.

PMID:
28866043
9.

Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12).

Yoshida K, Imamura CK, Hara K, Mochizuki M, Tanigawara Y.

Metabolomics. 2017;13(8):98. doi: 10.1007/s11306-017-1236-5. Epub 2017 Jul 7.

10.

Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia.

Kizu R, Nishimura K, Sato R, Kosaki K, Tanaka T, Tanigawara Y, Hasegawa T.

Horm Res Paediatr. 2017;88(5):316-323. doi: 10.1159/000478696. Epub 2017 Jul 14.

11.

The effects of advanced age and serum α1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients.

Kenmotsu H, Imamura CK, Ono A, Omori S, Nakashima K, Wakuda K, Taira T, Naito T, Murakami H, Takahashi T, Tanigawara Y.

Br J Clin Pharmacol. 2017 Nov;83(11):2416-2425. doi: 10.1111/bcp.13354. Epub 2017 Aug 17. Erratum in: Br J Clin Pharmacol. 2018 Oct;84(10):2449.

12.

Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients.

Ose A, Serada M, Yamashita K, Tsurui K, Tanigawara Y.

J Clin Pharmacol. 2017 Dec;57(12):1545-1553. doi: 10.1002/jcph.949. Epub 2017 Jun 14.

PMID:
28614613
13.

Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.

Booka E, Imamura CK, Takeuchi H, Hamamoto Y, Gomi D, Mizukami T, Ichiyama T, Tateishi K, Takahashi T, Kawakubo H, Soejima K, Boku N, Tanigawara Y, Kitagawa Y.

Gastric Cancer. 2016 Jul;19(3):876-86. doi: 10.1007/s10120-015-0536-6. Epub 2015 Aug 25.

14.

[Pharmacokinetic issues on cancer pharmacotherapy].

Tanigawara Y.

Nihon Rinsho. 2015 Aug;73(8):1357-63. Review. Japanese.

PMID:
26281690
15.

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.

Imamura CK, Furihata K, Okamoto S, Tanigawara Y.

J Clin Pharmacol. 2016 Apr;56(4):408-13. doi: 10.1002/jcph.605. Epub 2015 Oct 8.

16.

[The survey for anti-emetic guideline by using questioner].

Saeki T, Tamura K, Aiba K, Aogi K, Iino K, Imamura C, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Matsuura K, Wada M, Akechi T, Kakudo Y, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Saito M, Ashikaga Y, Tanigawara Y, Hirata K, Ishioka C, Nishiyama M.

Gan To Kagaku Ryoho. 2015 Mar;42(3):305-11. Japanese.

PMID:
25812498
17.

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.

Kenmotsu H, Tanigawara Y.

Cancer Sci. 2015 May;106(5):497-504. doi: 10.1111/cas.12647. Epub 2015 Mar 25. Review.

18.

Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.

Miura Y, Imamura CK, Fukunaga K, Katsuyama Y, Suyama K, Okaneya T, Mushiroda T, Ando Y, Takano T, Tanigawara Y.

BMC Cancer. 2014 Dec 16;14:964. doi: 10.1186/1471-2407-14-964.

19.

Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells.

Suzuki S, Tanigawara Y.

Proteome Sci. 2014 May 9;12:26. doi: 10.1186/1477-5956-12-26. eCollection 2014.

20.

Population PK modelling and simulation based on fluoxetine and norfluoxetine concentrations in milk: a milk concentration-based prediction model.

Tanoshima R, Bournissen FG, Tanigawara Y, Kristensen JH, Taddio A, Ilett KF, Begg EJ, Wallach I, Ito S.

Br J Clin Pharmacol. 2014 Oct;78(4):918-28. doi: 10.1111/bcp.12409.

21.

Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Okada K, Kimura T, Mikamo H, Kasahara K, Seki M, Takakura S, Tokimatsu I, Ohmagari N, Takahashi Y, Matsumoto K, Igarashi M, Kobayashi M, Hamada Y, Mochizuki T, Kimura M, Nishi Y, Tanigawara Y, Takesue Y; Japanese Society of Chemotherapy; Japanese Society of Therapeutic Drug Monitoring.

J Infect Chemother. 2014 Jan;20(1):1-5. doi: 10.1016/j.jiac.2013.08.008. Epub 2013 Dec 11.

22.

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.

Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D.

J Hum Genet. 2013 Dec;58(12):794-8. doi: 10.1038/jhg.2013.105. Epub 2013 Oct 3. Erratum in: J Hum Genet. 2013 Dec;58(12):825.

PMID:
24088669
23.

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.

Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35. doi: 10.1007/s00280-013-2258-y. Epub 2013 Sep 8.

PMID:
24013576
24.

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y.

J Infect Chemother. 2013 Jun;19(3):381-92. doi: 10.1007/s10156-013-0607-8. Epub 2013 May 15. No abstract available.

25.

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T.

J Infect Chemother. 2013 Jun;19(3):365-80. doi: 10.1007/s10156-013-0599-4. Epub 2013 May 15. No abstract available.

26.

Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.

Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A.

J Infect Chemother. 2013 Oct;19(5):858-66. doi: 10.1007/s10156-013-0580-2. Epub 2013 Mar 26.

27.

Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.

Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, Tanigawara Y.

J Infect Chemother. 2013 Jun;19(3):486-94. doi: 10.1007/s10156-012-0543-z. Epub 2013 Mar 23.

PMID:
23525983
28.

Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.

Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Tanigawara Y, Cash HL, Kohno S.

J Infect Chemother. 2013 Jun;19(3):472-9. doi: 10.1007/s10156-012-0514-4. Epub 2012 Nov 18.

PMID:
23179958
29.

Blood-direct InvaderPlus® as a new method for genetic testing.

Hirasawa A, Akahane T, Tanigawara Y, Aoki D.

Per Med. 2012 Aug;9(6):657-663. doi: 10.2217/pme.12.71.

PMID:
29768795
30.

Pharmacokinetics of mizoribine in adult living donor liver transplantation.

Shinoda M, Tanabe M, Kawachi S, Ono Y, Hayakawa T, Iketani O, Kojima M, Itano O, Obara H, Kitago M, Hibi T, Matsubara K, Shimojima N, Fuchimoto Y, Hoshino K, Wakabayashi G, Shimazu M, Tanigawara Y, Kuroda T, Morikawa Y, Kitajima M, Kitagawa Y.

Transplant Proc. 2012 Jun;44(5):1329-35. doi: 10.1016/j.transproceed.2012.01.139.

PMID:
22664010
31.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.

Oncol Rep. 2012 May;27(5):1393-9. doi: 10.3892/or.2012.1660. Epub 2012 Jan 26.

PMID:
22293824
32.

S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells.

Suzuki S, Yamayoshi Y, Nishimuta A, Tanigawara Y.

Proteome Sci. 2011 Dec 30;9:76. doi: 10.1186/1477-5956-9-76.

33.

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.

Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, Tanigawara Y, Imamura CK, Flockhart DA, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.

Hum Mol Genet. 2012 Apr 1;21(7):1665-72. doi: 10.1093/hmg/ddr597. Epub 2011 Dec 16.

PMID:
22180457
34.

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.

Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H.

Breast Cancer Res Treat. 2012 Jan;131(1):137-45. doi: 10.1007/s10549-011-1777-7. Epub 2011 Sep 23.

PMID:
21947681
35.

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.

Tanigawara Y, Nozawa K, Tsuda H.

Eur J Clin Pharmacol. 2012 Jan;68(1):39-53. doi: 10.1007/s00228-011-1095-3. Epub 2011 Jul 28.

36.

A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.

Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T.

Bone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 19.

37.

Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.

Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y.

J Infect Chemother. 2011 Dec;17(6):831-41. doi: 10.1007/s10156-011-0271-9. Epub 2011 Jul 20.

PMID:
21773752
38.

Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.

Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y.

Drug Metab Pharmacokinet. 2011;26(5):523-31. Epub 2011 Jul 12.

39.

Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.

Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K, Itoh H, Auwerx J.

J Biol Chem. 2011 Jul 29;286(30):26913-20. doi: 10.1074/jbc.M111.248203. Epub 2011 Jun 1.

40.

Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects.

Tsuruta K, Yamada Y, Serada M, Tanigawara Y.

J Clin Pharmacol. 2011 Sep;51(9):1276-85. doi: 10.1177/0091270010381900. Epub 2010 Nov 23.

PMID:
21098690
41.

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.

Hirose T, Fujita K, Nishimura K, Ishida H, Yamashita K, Sunakawa Y, Mizuno K, Miwa K, Nagashima F, Tanigawara Y, Adachi M, Sasaki Y.

Oncol Rep. 2010 Aug;24(2):529-36.

PMID:
20596643
42.

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.

Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.

J Clin Oncol. 2010 Mar 10;28(8):1287-93. doi: 10.1200/JCO.2009.25.7246. Epub 2010 Feb 1.

43.

Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.

Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T.

Oncol Res. 2009;17(11-12):527-33.

PMID:
19806783
44.

[Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure].

Kamata H, Asano K, Soejima K, Shirahata T, Nakatani M, Inamoto H, Iketani O, Yamayoshi Y, Tanigawara Y, Ishizaka A.

Gan To Kagaku Ryoho. 2009 Sep;36(9):1529-32. Japanese.

PMID:
19755826
45.
46.

Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics.

Asano K, Nakade S, Shiomi T, Nakajima T, Suzuki Y, Fukunaga K, Oguma T, Sayama K, Fujita H, Tanigawara Y, Ishizaka A.

Respirology. 2009 Aug;14(6):822-7. doi: 10.1111/j.1440-1843.2009.01552.x.

PMID:
19703064
47.

A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.

Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, Saijo N.

Jpn J Clin Oncol. 2009 Jul;39(7):425-30. doi: 10.1093/jjco/hyp038. Epub 2009 Apr 24.

PMID:
19395467
48.

A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.

Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S.

Cancer Chemother Pharmacol. 2009 Aug;64(3):557-64. doi: 10.1007/s00280-008-0904-6. Epub 2009 Jan 24.

PMID:
19169687
49.

Population pharmacokinetics of landiolol hydrochloride in healthy subjects.

Honda N, Nakade S, Kasai H, Hashimoto Y, Ohno T, Kitagawa J, Yamauchi A, Hasegawa C, Kikawa S, Kunisawa T, Tanigawara Y, Miyata Y.

Drug Metab Pharmacokinet. 2008;23(6):447-55.

50.

Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNA.

Komoto C, Nakamura T, Yamamori M, Ohmoto N, Kobayashi H, Kuwahara A, Nishiguchi K, Takara K, Tanigawara Y, Okamura N, Okumura K, Sakaeda T.

Kobe J Med Sci. 2008 Feb 8;53(6):355-63.

Supplemental Content

Loading ...
Support Center